Form 8-K - Current report:
SEC Accession No. 0001493152-24-039586
Filing Date
2024-10-04
Accepted
2024-10-04 17:29:56
Documents
14
Period of Report
2024-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41650
2 ex10-1.htm EX-10.1 41998
  Complete submission text file 0001493152-24-039586.txt   270605

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE kapa-20241001.xsd EX-101.SCH 3027
4 XBRL LABEL FILE kapa-20241001_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE kapa-20241001_pre.xml EX-101.PRE 24173
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3799
Mailing Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064
Business Address 2355 WESTWOOD BLVD. #139 LOS ANGELES CA 90064 818-404-5541
Kairos Pharma, LTD. (Filer) CIK: 0001962011 (see all company filings)

EIN.: 462993314 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42275 | Film No.: 241355767
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)